GUIDED THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $767.0K | $7.0K | $98.0K | $13.0K | $81.0K | $102.0K | $36.0K | $57.0K |
| Cost of Revenue | $196.0K | $5.0K | $62.0K | $81.0K | $61.0K | $-41.0K | $70.0K | $89.0K |
| Gross Profit | $571.0K | $2.0K | $36.0K | $-68.0K | $20.0K | $143.0K | $-34.0K | $-32.0K |
| Gross Margin | 74.4% | 28.6% | 36.7% | -523.1% | 24.7% | 140.2% | -94.4% | -56.1% |
| Operating Expenses | ||||||||
| Research & Development | $469.0K | $526.0K | $228.0K | $77.0K | $69.0K | $143.0K | $122.0K | $244.0K |
| SG&A Expense | $2.3M | $1.3M | $3.0M | $3.0M | $2.2M | $913.0K | $694.0K | $1.1M |
| Operating Income | $-2.4M | $-2.1M | $-3.5M | $-3.3M | $-2.4M | $-1.1M | $-937.0K | $-1.5M |
| Operating Margin | -309.3% | -30,114.3% | -3,527.6% | -25,638.5% | -2,916.0% | -1,031.4% | -2,602.8% | -2,715.8% |
| Interest Expense | $617.0K | $381.0K | $278.0K | $582.0K | $1.2M | $1.1M | $1.4M | $1.8M |
| Pretax Income | $-3.2M | $-2.4M | $-3.5M | $-4.3M | $-2.1M | $-279.0K | $-1.9M | $1.0M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-3.2M | $-2.4M | $-3.5M | $-4.3M | $-2.1M | $-279.0K | $-1.9M | $1.0M |
| Net Margin | -416.7% | -34,528.6% | -3,560.2% | -33,392.3% | -2,555.6% | -273.5% | -5,336.1% | 1,782.5% |
| EPS (Basic) | $-0.04 | $-0.05 | $-0.07 | $-0.15 | $-0.09 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.04 | $-0.05 | $-0.07 | $-0.15 | $-0.09 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 78.4M | 57.3M | — | 32.5M | 26.8M | 26.75B | 24.6M | 3.4M |
| Shares Outstanding (Diluted) | 78.4M | 57.3M | 51.1M | 32.5M | 26.8M | 26.7M | 24.6M | 486.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |